Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
NCT00054834
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
27
Enrollment
INDUSTRY
Sponsor class
Stopped
lack of accrual
Conditions
Non-Hodgkins Lymphoma
Interventions
DRUG:
hLL2 (epratuzumab)
Sponsor
Gilead Sciences